Biodesix Inc
NASDAQ:BDSX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.19
2.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biodesix Inc
Biodesix Inc
Accounts Receivables
Biodesix Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biodesix Inc
NASDAQ:BDSX
|
Accounts Receivables
$7.7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Accounts Receivables
$2.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Accounts Receivables
$1.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
CVS Health Corp
NYSE:CVS
|
Accounts Receivables
$9.9B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
|
|
Cigna Corp
NYSE:CI
|
Accounts Receivables
$27.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Accounts Receivables
$2.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
See Also
What is Biodesix Inc's Accounts Receivables?
Accounts Receivables
7.7m
USD
Based on the financial report for Dec 31, 2023, Biodesix Inc's Accounts Receivables amounts to 7.7m USD.
What is Biodesix Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
32%
Over the last year, the Accounts Receivables growth was 51%. The average annual Accounts Receivables growth rates for Biodesix Inc have been -21% over the past three years , 32% over the past five years .
You don't have any saved screeners yet
